Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Dichloroacetic Acid. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 2/20 | 0.59 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.47 |
| ▸ | TP53 | P04637 | 1/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 8/20 | 0.38 |
| ▸ | SLC7A5 | Q01650 | 1/20 | 0.33 |
| ▸ | MEN1 | O00255 | 2/20 | 0.32 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.32 |
| ▸ | GAA | P10253 | 1/20 | 0.32 |
| ▸ | HPGD | P15428 | 2/20 | 0.31 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.31 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.31 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.30 |
| ▸ | MAPT | P10636 | 1/20 | 0.30 |
| ▸ | HTT | P42858 | 1/20 | 0.30 |
| ▸ | FOLH1 | Q04609 | 2/20 | 0.30 |
| ▸ | NAALAD2 | Q9Y3Q0 | 2/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Dichloroacetic Acid SCHEMBL27684305 | 0.95 | LMNA (0.53) | LMNATDP1TP53ALDH1A1SLC7A5 | |
| Bicarbonate SCHEMBL8871100 | 0.81 | TDP1 (0.61) | LMNATDP1TP53ALDH1A1SLC7A5 | |
| Dichloroacetic Acid SCHEMBL5874158 | 0.80 | LMNA (0.56) | LMNATP53ALDH1A1SLC7A5 | |
| Lactic Acid SCHEMBL5671703 | 0.79 | TP53 (0.69) | LMNATDP1TP53ALDH1A1SLC7A5 | |
| Dichloroacetic Acid SCHEMBL5874373 | 0.78 | — | — | |
| Acetic Acid SCHEMBL1114492 | 0.78 | TDP1 (0.57) | LMNATDP1TP53ALDH1A1GAA | |
| Oxalic Acid SCHEMBL21145223 | 0.78 | TDP1 (0.57) | TDP1TP53ALDH1A1SLC7A5GAA | |
| Dichloroacetic Acid SCHEMBL9560991 | 0.78 | LMNA (0.71) | LMNATP53ALDH1A1SLC7A5 | |
| Oxalic Acid SCHEMBL21145225 | 0.78 | TDP1 (0.57) | TDP1TP53ALDH1A1SLC7A5GAA | |
| Bicarbonate SCHEMBL20542224 | 0.78 | TDP1 (0.57) | LMNATDP1TP53ALDH1A1SLC7A5 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1403 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12605345-B2 | Transdermal drug delivery system | BioPhysics Pharma, Inc. (US) | 2026-04-21 | — | — | US | claimed |
| US-20250268841-A1 | Trans-Epithelial Membrane Drug Delivery System | Masiz, John J. (US) | 2025-08-28 | — | — | US | claimed |
| CN-119708799-B | Cured product of organic phosphine modified unsaturated polyester and polyhalide and preparation method thereof | 浙江工业大学 | 2025-05-30 | — | — | CN | claimed |
| US-20250120907-A1 | Transmucosal Drug Delivery System | Masiz, John J. (US) | 2025-04-17 | — | — | US | claimed |
| CN-119708799-A | Cured product of organic phosphine modified unsaturated polyester and polyhalide and preparation method thereof | 浙江工业大学 | 2025-03-28 | — | — | CN | claimed |
| US-12246098-B2 | Trans-epithelial membrane drug delivery system | BioPhysics Pharma, Inc. (US) | 2025-03-11 | — | — | US | claimed |
| US-20240216292-A1 | Trans-Epithelial Membrane Drug Delivery System | Masiz, John J. (US) | 2024-07-04 | — | — | US | claimed |
| US-20240108588-A1 | Transdermal Drug Delivery System | Masiz, John J. (US) | 2024-04-04 | — | — | US | claimed |
| US-11865217-B2 | Transdermal drug delivery system | BioPhysics Pharma, Inc. (US) | 2024-01-09 | — | — | US | claimed |
| WO-2023183932-A2 | MONOBODIES BINDING TO INTERCELLULAR ADHESION MOLECULE 2 (ICAM-2) | NEW YORK UNIVERSITY (US) | 2023-09-28 | — | — | WO | claimed |
| CN-1433766-A | Medicine for treating metabolism syndrome | LIAONING YILIAN NOVEL MEDICINE (CN) | 2003-08-06 | — | — | CN | claimed |
| WO-2002087556-A9 | PROBUCOL MONOESTERS AND THEIR USE TO INCREASE PLASMA HDL CHOLESTEROL LEVELS AND IMPROVE HDL FUNCTIONALITY | ATHEROGENICS INC (US) | 2003-03-20 | — | — | WO | claimed |
| WO-2002087556-A2 | PROBUCOL MONOESTERS AND THEIR USE TO INCREASE PLASMA HDL CHOLESTEROL LEVELS AND IMPROVE HDL FUNCTIONALITY | ATHEROGENICS, INC. (US) | 2002-11-07 | — | — | WO | claimed |
| WO-2002072039-A2 | TOPICAL PREPARATIONS AND FOOD PREPARATIONS COMPRISING A PYRIDOXINE-ALPHA-D-GLUCOSE | PENTAPHARM LTD (CH) | 2002-09-19 | — | — | WO | claimed |
| CN-1294519-A | Pharmaceutical composition containing a compound having an activity of promoting the absorption of an active ingredient | INPHARMA SA (CH) | 2001-05-09 | — | — | CN | claimed |
| EP-1073470-A1 | PHARMACEUTICAL COMPOSITIONS CONTAINING COMPOUNDS WITH ACTIVITY FOR THE ENHANCEMENT OF ABSORPTION OF ACTIVE INGREDIENTS | INPHARMA S.A. (CH) | 2001-02-07 | — | — | EP | claimed |
| WO-2000048636-A1 | PHARMACEUTICAL COMPOSITIONS CONTAINING COMPOUNDS WITH ACTIVITY FOR THE ENHANCEMENT OF ABSORPTION OF ACTIVE INGREDIENTS | INPHARMA S.A. (CH) | 2000-08-24 | — | — | WO | claimed |
| US-5811547-A | Method for inducing crystalline state transition in medicinal substance | NIPPON SHINYAJU CO., LTD. (JP) | 1998-09-22 | — | — | US | claimed |
| EP-0304897-A2 | Process for immunizing the human body at HIV infections | Steglich, Burkhard (DE) | 1989-03-01 | — | — | EP | claimed |
| US-4631294-A | TRAUMAS, STROKES, CARDIOVASCULAR DISORDERS | UNIVERSITY E.M., INC. (US) | 1986-12-23 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12605345-B2 | Transdermal drug delivery system | FABP2, VEGFA, CUTA | LMNA 512/4885TDP1 1999/4885TP53 1854/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.